Better After CHoosing. Randomly Allocated or Patient Preference Based Treatment With Filgotinib or TNFi in RA (BACH)

Inclusion Criteria: Demographic and general characteristics: * Adult male or female patients, at least 18 years of age. * Able and willing to give written informed consent. * Have sufficient knowledge of the Dutch language to be able to comply with the requirements of the study protocol. Inclusion criteria: * Diagnosis of adult-onset RA as defined by the 2010 ACR/ EULAR Rheumatoid arthritis classification criteria; * Diagnosis of RA for ≥ three months; * Are being treated ≥ three months with ≥ 1 csDMARD therapy; * Have had an inadequate response or intolerance to at least 1 csDMARD; * Have moderately to severely active RA to the discretion of the rheumatologist or defined as a DAS28 ≥ 3.2 at screening and baseline visits; * Subjects must have been on a stable dose of csDMARD therapy (restricted to methotrexate, chloroquine, hydroxychloroquine, sulfasalazine, or leflunomide) for ≥ 4 weeks prior to the baseline visit. Exclusion Criteria: * Previous treatment with any biological DMARD or targeted synthetic DMARD/JAKi; * Inflammatory rheumatic disease other than RA, except for secondary Sjögren's syndrome. * Having a contraindication for either TNFi or filgotinib; * Latent or active tuberculosis; * Active or recurrent infections; * History of any malignancy within 5 years except for successfully treated NMSC or localized carcinoma in situ of the cervix; * ≥ 3x upper limit of normal ALT, AST; * eGFR ≤ 30 ml/min; * planned or actual pregnancy or planning to father a child.